Although GM-CSF was used as an adjuvant in vaccines to treat NSCLC and pancreatic cancer, the extent to which GM-CSF increases the efficacy of the cancer vaccines used in these studies remains unknown. This evidence concerns the gene CSF2 and non-small cell lung carcinoma.